Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beiyun Chen

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
The American Surgeon|May 2, 2018
Ability of Intraoperative Pathologic Analysis of Ductal Carcinoma <i>In Situ</i> to Guide Selective Use of Sentinel Lymph Node SurgeryBrittany L Murphy, Alexandra B Gonzalez, Michael G Keeney, et al.
Breast Cancer Research : BCR|May 15, 2012
Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancerLuigi Strizzi, Katharine M Hardy, Naira V Margaryan, et al.
Breast Cancer Research and Treatment|January 8, 2014
Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring studyAnn E McCullough, Patrizia Dell'orto, Monica M Reinholz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2011
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancerEdith A Perez, Vera J Suman, Nancy E Davidson, et al.
Breast Cancer Research and Treatment|April 14, 2021
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)Tufia C Haddad, Jun He, Ciara C O'Sullivan, et al.
Archives of Pathology & Laboratory Medicine|August 17, 2022
Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant ChemotherapySunati Sahoo, Gregor Krings, Yunn-Yi Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2013
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trialEdith A Perez, Amylou C Dueck, Ann E McCullough, et al.
Breast Cancer Research and Treatment|February 20, 2013
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)Edith A Perez, Michael F Press, Amylou C Dueck, et al.
Annals of Surgical Oncology|August 3, 2017
A Validated Nomogram to Predict Upstaging of Ductal Carcinoma in Situ to Invasive DiseaseJames W Jakub, Brittany L Murphy, Alexandra B Gonzalez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2013
Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831Amylou C Dueck, Monica M Reinholz, Xochiquetzal J Geiger, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
The American Surgeon|May 2, 2018
Ability of Intraoperative Pathologic Analysis of Ductal Carcinoma <i>In Situ</i> to Guide Selective Use of Sentinel Lymph Node SurgeryBrittany L Murphy, Alexandra B Gonzalez, Michael G Keeney, et al.
Breast Cancer Research : BCR|May 15, 2012
Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancerLuigi Strizzi, Katharine M Hardy, Naira V Margaryan, et al.
Breast Cancer Research and Treatment|January 8, 2014
Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring studyAnn E McCullough, Patrizia Dell'orto, Monica M Reinholz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2011
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancerEdith A Perez, Vera J Suman, Nancy E Davidson, et al.
Breast Cancer Research and Treatment|April 14, 2021
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)Tufia C Haddad, Jun He, Ciara C O'Sullivan, et al.
Archives of Pathology & Laboratory Medicine|August 17, 2022
Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant ChemotherapySunati Sahoo, Gregor Krings, Yunn-Yi Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2013
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trialEdith A Perez, Amylou C Dueck, Ann E McCullough, et al.
Breast Cancer Research and Treatment|February 20, 2013
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)Edith A Perez, Michael F Press, Amylou C Dueck, et al.
Annals of Surgical Oncology|August 3, 2017
A Validated Nomogram to Predict Upstaging of Ductal Carcinoma in Situ to Invasive DiseaseJames W Jakub, Brittany L Murphy, Alexandra B Gonzalez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2013
Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831Amylou C Dueck, Monica M Reinholz, Xochiquetzal J Geiger, et al.
Pageof 7